The FGFR1 and FGFR3 inhibitor BGJ398 was investigated in a phase II clinical trial for FGFR1-amplified lung cancer and FGFR1/2-amplified and FGFR3-mutant breast cancer [35]. Here, FGFR3 is linked to breast cancer.